MTI-201

N/A

Report date: 2026/01/27 16:11:03

Base Information

Drug NameMTI-201
Drug Alias Name225Ac-MC1RL-DOTA225Ac-DOTA-MTI-201225Ac-DOTA-Ahx-MC1RLActinium-225-MC1RL-DOTADOTA-Ahx-MC1RL-[225Ac] +[10] 
ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225Ac +[5] 
Mechanisms of ActionMelanocortin receptor 1 modulatorsIonising radiation emitters
TargetsMelanocortin receptor 1
Therapy Area/IndicationsUveal melanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesModulation Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesModulation Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsUveal melanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A